MA-SAPPI
26.4.2022 10:02:13 CEST | Business Wire | Press release
Sappi , a leading producer and supplier of diversified paper, packaging products and dissolving pulp, today launched Arrio, a decorative laminate surface solution that delivers remarkable aesthetics, premium haptics and scratch and fingerprint resistance for high-wear surfaces. By designing Arrio to serve the unmet needs of customers, Sappi will now become the only company that provides high-fidelity, 100% replicated textured finished surfaces available in flat, then expanding to include a 3D texture library over time.
With its durable acrylic surface, Arrio provides extraordinarily detailed, realistic finished surfaces that will eventually support multiple textures and décor colors, gloss effects, varying depths and visible contrast. Sappi’s high-precision manufacturing process generates the exact same surface finish over time without variation or loss of definition. Arrio, which offers a superior surface to conventional melamine in aesthetics and performance, is a perfect solution for decorative and functional surfaces on furniture, work surfaces, kitchen cabinetry and more.
“We are excited to introduce Arrio, which is not a mold that imparts texture, but is the actual finished surface,” said Mark Hittie, Director of Release Strategy, Sappi Casting and Release. “Arrio comes from Sappi’s spirit and core competence: we make texture, we drive texture. It’s another example of Sappi delivering a high-quality and innovative product that outperforms traditional options, reduces cost and opens up a range of possibilities for consumers. We’re also proud that Sappi created Arrio with sustainability in mind. The durable acrylic surface extends product lifetime and does not require application or removal of protective film layers, thus reducing manufacturing costs and waste.”
Unlike surfaces produced with an excimer process, Arrio will offer a uniquely customizable surface texture, including various flat finishes and textures with multiple gloss levels, such as wood or stone designs. The manufacturing process provides 100% consistency, order to order, in texture, gloss, touch and function. Arrio provides a superior solution over existing concepts because of its endless potential for customization. It also provides superior haptics, including super matte, smooth touch and high-color intensity surfaces, and it is suitable for single radius wrapping applications.
Arrio also offers significantly lower investment costs for glued and pressed finished surfaces due to manufacturers’ savings and efficiencies in the handling, shipping and layup processes.
Offered initially in a supermatte, fingerprint resistant, soft touch texture called Matte Haven on black décor, the Arrio platform will continue to develop with the future addition of texture and décor color options.
Sappi’s forward-looking products and textures continue to leverage state-of-the-art technology from its Westbrook Mill in Maine. Sappi has been at the forefront of technological innovation and evolution in the release paper industry with nearly 80 years of experience creating textures.
To request a launch kit for Arrio, please contact your Sappi sales representative. To learn more about Arrio and Sappi’s casting and release papers, please visit: www.sappi.com/sappi-casting-release-papers .
About Sappi North America, Inc.
Sappi North America, Inc., headquartered in Boston, is a market leader in converting wood fiber into superior products that customers demand worldwide. The success of our diversified businesses – high-quality Coated Graphic Papers, Dissolving Pulp, and Packaging and Specialty Papers – is driven by strong customer relationships, best-in-class people and advantaged assets, products and services. Our high-quality Graphic Papers, including McCoy, Opus, Somerset and Flo, are the key platform for premium magazines, catalogs, books, direct mail and high-end print advertising. We are a leading manufacturer of Dissolving Pulp with our Verve brand, a sustainable fiber that is used in a wide range of products, including textile fibers and household goods. We deliver sustainable Packaging and Specialty Papers for luxury packaging and folding carton applications with our single-ply packaging brands, Spectro and Proto, and for the food and label industries with our specialty paper, LusterCote. We are also one of the world's leading suppliers of Casting and Release Papers with our Ultracast, PolyEx and Classics lines for the automotive, fashion and engineered films industries. Customers rely on Sappi for high technical, operational and market expertise; products and services delivered with consistently high quality and reliability; and, state-of-the-art and cost-competitive assets and innovative spirit.
Sappi North America is a subsidiary of Sappi Limited (JSE), a global company headquartered in Johannesburg, South Africa, with more than 12,000 employees and manufacturing operations on three continents in seven countries and customers in over 150 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005523/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
